Two major randomized clinical trials “Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source” (RE-SPECT ESUS) and “New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus Aspirin to Prevent Embolism in Embolic Stroke of Undetermined Source” (NAVIGATE ESUS) aimed to determine the best treatment approach for ESUS. The gene discussed is F10; the disease is Stroke.